title: Gemcitabine and s-1 combination chemotherapy in patients with advanced biliary tract cancer: a retrospective study.
abstract: BACKGROUND
  The aim of this study was to investigate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
  
  
  METHODS
  A retrospective study was performed on 15 consecutive patients. Gemcitabine was administered intravenously at 1,000 mg/m(2) on days 8 and 15. Oral S-1 (60 mg/m(2) in 2 divided doses) was given daily for the first 2 weeks, followed by 1 week of rest. This 3-week course of treatment was repeated. The primary endpoint was response rate, and the secondary endpoints were overall survival, progression-free survival, and safety.
  
  
  RESULTS
  The overall response rate was 26.7%, and the disease control rate was 73.4%. The overall survival was 12.0 months (95% CI, 9.5-14.5 months), and the progression-free survival was 8.0 months (95% CI, 4.3-11.7 months). Adverse events of grade 3 or 4 occurred in 33.3%, and the major grade 3/4 toxicities were anemia (20.0%), leukopenia (13.3%), and anorexia (13.3%).
  
  
  CONCLUSIONS
  Gemcitabine and S-1 combination chemotherapy is effective and safe in patients with advanced biliary tract cancer.
authors: Department of Surgery, New-Tokyo Hospital, Matsudo, Japan.
authors: Kazuhito
authors: K
authors: Mita
authors: Hideto
authors: H
authors: Ito
authors: Masato
authors: M
authors: Fukumoto
authors: Ryo
authors: R
authors: Murabayashi
authors: Masashi
authors: M
authors: Nabetani
authors: Kazuya
authors: K
authors: Koizumi
authors: Takashi
authors: T
authors: Hayashi
references: J Clin Oncol. 2006 Mar 1;24(7):1152-60
references: 16505435
references: Cancer Chemother Pharmacol. 2010 May;65(6):1101-7
references: 19707761
references: BMC Cancer. 2002 May 03;2:10
references: 11991810
references: Oncology. 2009;77(1):71-4
references: 19556812
references: Ann Oncol. 2004 Sep;15(9):1339-43
references: 15319238
references: Br J Cancer. 2009 Aug 18;101(4):621-7
references: 19672264
references: Ann Oncol. 1996 Aug;7(6):593-600
references: 8879373
references: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references: 10655437
references: Br J Cancer. 2007 Mar 26;96(6):896-902
references: 17325704
references: Cancer Chemother Pharmacol. 2008 Oct;62(5):849-55
references: 18214482
references: N Engl J Med. 2010 Apr 8;362(14):1273-81
references: 20375404
references: Ann Oncol. 2001 Feb;12(2):183-6
references: 11300321
references: Ann Oncol. 2001 Oct;12(10):1403-6
references: 11762811
references: Br J Cancer. 2008 Sep 16;99(6):862-7
references: 19238628
references: J Clin Oncol. 2005 Apr 1;23(10):2332-8
references: 15800324